Stock SYRS SYROS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
5.58 USD +5.08% Intraday chart for Syros Pharmaceuticals, Inc. -7.00% -28.37%
06-05 Transcript : Syros Pharmaceuticals, Inc. - Shareholder/Analyst Call
05-14 Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Syros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
MT
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise
MT
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
CI
Health Care Rises as Upward Momentum Builds -- Health Care Roundup
DJ
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000
MT
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene
MT
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial
CI
Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
CI
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q3 Revenue $3.8M, vs. Street Est of $3.9M
MT
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Syros Pharmaceuticals, Inc. Receives Notice from Incyte Corporation to Terminate the Target Discovery, Research Collaboration and Option Agreement
CI
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q2 Revenue $2.8M, vs. Street Est of $3.5M
MT
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Syros Pharmaceuticals Shares Fall After Pfizer Terminates License, Collaboration
MT
Syros Pharmaceuticals, Inc. Announces Terminate the License and Collaboration Agreement with Global Blood Therapeutics, Inc
CI
Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
CI
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Posts Q1 Revenue $3M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYRS Stock
  4. News Syros Pharmaceuticals, Inc.
  5. Highlights